InnerScope Hearing Technologies, Inc. (INND)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
InnerScope Hearing Technologies, Inc. (INND) trades at $0.00. InnerScope Hearing Technologies, Inc. Market cap: $306, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for INND: INND does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INND against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INND: 1/1 perspectives are bearish.
How is this calculated? →InnerScope Hearing Technologies, Inc. (INND) Healthcare & Pipeline Overview
InnerScope Hearing Technologies, Inc. is a healthcare company focused on direct-to-consumer hearing solutions, manufacturing and distributing hearing aids, personal sound amplification devices, and related wellness products. It also operates audiological clinics and offers a B2B patient management SaaS platform, addressing the growing demand for accessible hearing technology.
What Is the Investment Thesis for INND?
InnerScope Hearing Technologies, Inc. operates in the expanding direct-to-consumer hearing aid market, driven by an aging global population and increasing demand for accessible, affordable hearing solutions. The company's diversified business model, encompassing manufacturing, direct sales, a network of eleven audiological clinics, and a B2B SaaS patient management platform, positions it to capture various segments of the hearing health market. Its unique offerings, such as physician-developed dietary supplements and a CBD oil for tinnitus, represent potential niche market opportunities within the broader healthcare sector. However, the company's financial performance, characterized by a significant negative profit margin of -267.1% and a negative gross margin of -81.5%, indicates substantial operational challenges and a lack of profitability. With a market capitalization of 306 (effectively $613 as per AI Insight) and trading on the OTC Other tier, INND faces considerable risks related to limited liquidity, high volatility, and potential difficulties in securing necessary funding to execute its business plan. Investors evaluating INND must consider its strategic positioning in a growing market against its current financial instability and the inherent risks of an OTC-listed microcap stock.
Based on FMP financials and quantitative analysis
INND Key Highlights
- Market Capitalization: $0.00B, indicating a microcap status and potential for high volatility.
- Profit Margin: -267.1%, reflecting significant unprofitability in its current operations.
- Gross Margin: -81.5%, suggesting that the cost of goods sold substantially exceeds revenue.
- Beta: 1.45, indicating higher volatility compared to the overall market.
- Employee Count: 26 employees, signifying a relatively small operational scale for a company with diverse offerings.
Who Are INND's Competitors?
INND is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.62 | -8.47% | $64.16M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| SARTF Sartorius AG | $212.80 | +0.00% | $14.69B | 51 |
| NSTG NanoString Technologies, Inc. | $0.11 | -37.43% | $5.07M | 51 |
| STAA STAAR Surgical Company | $27.45 | -1.21% | $1.37B | 51 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INND's Key Strengths?
- Diversified product portfolio including hearing aids, therapeutic treatments, supplements, and CBD oil.
- Integrated business model with direct-to-consumer sales, wholesale, and owned clinics.
- Proprietary B2B SaaS platform for patient management, offering a scalable service.
- Focus on affordable hearing solutions addresses a significant market demand.
What Are INND's Weaknesses?
- Significant unprofitability with negative profit margin (-267.1%) and gross margin (-81.5%).
- Very low market capitalization ($0.00B, or $613) indicating microcap status and high risk.
- Trades on the OTC Other tier, implying limited liquidity and disclosure.
- Small employee base (26 employees) for a company with diverse operations.
What Could Drive INND Stock Higher?
- Potential for increased market penetration of its direct-to-consumer hearing aid solutions through expanded marketing initiatives.
- Introduction of new models of hearing aids or personal sound amplification devices to address evolving consumer needs.
- Expansion of the B2B SaaS platform's client base through new partnership agreements with audiology practices.
- Growth in sales of physician-developed dietary supplements and the unique CBD oil for tinnitus, driven by increased consumer awareness.
- Strategic initiatives to improve operational efficiency and reduce negative profit and gross margins, potentially through cost optimization or revenue growth strategies.
What Are the Key Risks for INND?
- Financial-distress signal — its Altman Z-Score of -0.78 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-0.8%) — the business is not currently generating profit on shareholder capital.
- Significant unprofitability, evidenced by a -267.1% profit margin and -81.5% gross margin, indicating challenges in achieving sustainable operations.
- High market volatility and limited liquidity due to its microcap status and trading on the OTC Other tier, posing risks for investors seeking to enter or exit positions.
- Intense competition within the hearing aid and medical instruments market from larger, well-capitalized companies.
- Challenges in securing adequate funding to support ongoing operations, product development, and market expansion, given its current financial performance.
- Regulatory risks associated with the manufacturing and marketing of medical devices, dietary supplements, and CBD products, which can be subject to evolving compliance requirements.
What Are the Growth Opportunities for INND?
- Expansion of Direct-to-Consumer (D2C) Hearing Aid Market Penetration: The global market for hearing aids is expanding, driven by an aging population and increased awareness of hearing loss. InnerScope's focus on direct-to-consumer sales of affordable hearing aids and personal sound amplification devices positions it to capitalize on this trend. By bypassing traditional distribution channels, the company can potentially offer more competitive pricing, appealing to a wider demographic seeking accessible solutions. Continued investment in digital marketing and e-commerce platforms could significantly broaden its reach and market share over the next 3-5 years, tapping into a market estimated to reach over $10 billion globally by the end of the decade.
- Growth of Audiological and Retail Hearing Device Clinics Network: InnerScope currently manages and operates eleven audiological and retail hearing device clinics. Expanding this network, either through organic growth or strategic acquisitions, represents a significant growth opportunity. These clinics provide direct patient interaction, professional fitting services, and ongoing support, which can build customer loyalty and drive sales of InnerScope's devices and related services. Each new clinic can serve as a local hub for sales and service, potentially increasing revenue streams and market presence in specific geographic regions over a 2-4 year timeline, leveraging the demand for localized healthcare services.
- Development and Adoption of B2B SaaS Patient Management Platform: InnerScope's business-to-business (B2B) software-as-a-service (SaaS) platform for patient management offers a scalable revenue stream beyond hardware sales. As healthcare providers increasingly adopt digital solutions for efficiency, this platform can be marketed to independent audiology practices, hearing device retailers, and even larger clinic networks. Enhancing the platform's features, ensuring robust data security, and aggressive sales efforts could lead to wider adoption. The global healthcare IT market, including patient management systems, is projected for substantial growth, offering a multi-billion dollar opportunity over the next 5-7 years for specialized solutions.
- Diversification through Hearing-Related Therapeutic Treatments and Supplements: The company's offerings include hearing-related therapeutic treatments and physician-developed dietary supplements aimed at supporting hearing health. This diversification allows InnerScope to tap into the broader wellness market, which is experiencing significant growth as consumers seek proactive health solutions. Developing and marketing new formulations or expanding the distribution channels for existing supplements could open new revenue streams. The global dietary supplements market is valued in the hundreds of billions and is expected to continue growing, providing a substantial addressable market for these specialized products over a 3-5 year horizon.
- Market Penetration with Unique CBD Oil for Tinnitus Management: InnerScope offers a unique CBD oil specifically formulated for managing tinnitus. The market for CBD products is rapidly expanding, driven by increasing consumer acceptance and research into its potential therapeutic benefits. Tinnitus affects a significant portion of the population, and effective management solutions are in high demand. By focusing on a specialized application within the CBD market, InnerScope can carve out a niche. Strategic marketing, clinical validation (where appropriate), and navigating regulatory landscapes could position this product for considerable growth over the next 2-5 years, tapping into a segment of the wellness market.
What Opportunities Does INND Have?
- Growing global demand for affordable hearing solutions driven by an aging population.
- Expansion of its audiological and retail clinic network.
- Increased adoption of its B2B SaaS platform by other healthcare providers.
- Further development and market penetration of specialized wellness products like CBD oil for tinnitus.
What Threats Does INND Face?
- Intense competition from larger, more established hearing aid manufacturers.
- Challenges in securing adequate funding to support operations and growth initiatives.
- Regulatory changes impacting the sale and marketing of dietary supplements and CBD products.
- High market volatility and limited liquidity inherent with OTC Other tier stocks.
What Are INND's Competitive Advantages?
- Integrated Product and Service Ecosystem: Offers a comprehensive suite including hardware, clinics, therapeutic treatments, supplements, and SaaS, creating a more holistic customer experience.
- Specialized Product Offerings: Unique physician-developed dietary supplements and a CBD oil specifically formulated for tinnitus management differentiate its wellness portfolio.
- Direct-to-Consumer Distribution Model: Allows for potentially more competitive pricing and direct brand engagement, bypassing traditional intermediary costs.
- B2B SaaS Platform: Provides a recurring revenue stream and integrates the company deeper into the operational workflows of audiology practices.
What Does INND Do?
InnerScope Hearing Technologies, Inc. (INND) is a healthcare company established in 2012, initially incorporated as Innerscope Advertising Agency, Inc. The company underwent a significant transformation, officially adopting its current name in August 2017, reflecting its pivot towards the hearing technology sector. Headquartered in Roseville, California, InnerScope has evolved into a multifaceted provider of hearing solutions. Its core operations involve the manufacturing and direct-to-consumer distribution and sales of a diverse range of hearing aids and personal sound amplification devices, available in both hearable and wearable formats. This direct-to-consumer model aims to make hearing technology more accessible and affordable for a broad market. Beyond its hardware offerings, InnerScope has developed a comprehensive ecosystem of related products and services. This includes specialized hearing-related therapeutic treatments designed to support auditory health. The company also offers physician-developed dietary supplements, formulated with ingredients intended to bolster hearing wellness. A distinctive product in its portfolio is a unique CBD oil, specifically engineered for the management of tinnitus, addressing a common and often debilitating hearing-related condition. Further expanding its service delivery, InnerScope manages and operates a network of eleven audiological and retail hearing device clinics. These clinics provide direct patient care, fitting services, and support, integrating the company's products with professional audiological services. In a strategic move to enhance operational efficiency within the healthcare sector, InnerScope also provides a business-to-business (B2B) software-as-a-service (SaaS) platform. This platform is designed for patient management, offering a digital solution to streamline administrative and clinical workflows for audiology practices and hearing device retailers. Through this integrated approach, InnerScope aims to serve both individual consumers and the broader retail hearing aid community with a holistic suite of products and services.
What Products and Services Does INND Offer?
- Manufactures and distributes a range of hearing aids and personal sound amplification devices.
- Sells hearing devices directly to consumers through various channels.
- Supplies the retail hearing aid community with its products.
- Offers hearing-related therapeutic treatments.
- Provides physician-developed dietary supplements for hearing health.
- Markets a unique CBD oil specifically formulated for managing tinnitus.
- Manages and operates eleven audiological and retail hearing device clinics.
- Develops and provides a business-to-business (B2B) software-as-a-service (SaaS) platform for patient management.
How Does INND Make Money?
- Direct-to-Consumer (D2C) Sales: Generates revenue by selling hearing aids and personal sound amplification devices directly to end-users.
- Wholesale Distribution: Supplies its hearing devices to the retail hearing aid community.
- Service Revenue from Clinics: Earns income from audiological services, fittings, and sales conducted through its eleven owned and operated clinics.
- Product Sales (Supplements & CBD Oil): Derives revenue from the sale of physician-developed dietary supplements and specialized CBD oil for tinnitus.
- Software-as-a-Service (SaaS) Subscriptions: Collects recurring fees from businesses utilizing its B2B patient management platform.
What Industry Does INND Operate In?
InnerScope Hearing Technologies, Inc. operates within the Medical - Instruments & Supplies industry, a segment of the broader Healthcare sector. This industry is experiencing growth, largely fueled by an aging global population and increasing awareness of hearing health. The market for hearing aids and related devices is characterized by a shift towards more accessible and direct-to-consumer models, driven by technological advancements and regulatory changes. InnerScope positions itself within this evolving landscape by offering a range of affordable hearing solutions directly to consumers, alongside supplying the retail hearing aid community. The competitive landscape includes established global manufacturers, smaller specialized device companies, and a growing number of direct-to-consumer online retailers. InnerScope's strategy of combining hardware manufacturing, direct sales, audiological clinics, and a B2B SaaS platform aims to create a comprehensive ecosystem, differentiating it from competitors that may focus solely on device sales or clinical services. The demand for hearing health products and services is projected to continue expanding, presenting both opportunities and intense competition.
Who Are INND's Key Customers?
- Individual consumers seeking affordable and accessible hearing aids and personal sound amplification devices.
- Patients seeking therapeutic treatments and dietary supplements for hearing health.
- Individuals experiencing tinnitus who are looking for management solutions, specifically CBD oil.
- Retail hearing aid stores and audiology practices that purchase devices for resale.
- Audiological clinics and healthcare providers subscribing to its B2B patient management SaaS platform.
How InnerScope Hearing Technologies, Inc. Is Valued
InnerScope Hearing Technologies, Inc. carries a market capitalization of 306, placing it in the micro-cap category.
Company Profile
InnerScope Hearing Technologies, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Roseville, US. The company is led by CEO Matthew Ross Moore. INND has traded publicly since 2017.
ROE -1%Key Financial Metrics
Return on equity for InnerScope Hearing Technologies, Inc. stands at -0.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.5%, showing how much profit it generates from its asset base. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 4/9Financial Health
InnerScope Hearing Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.78 places it in the distress zone, a signal of elevated financial risk.
Net sellingInsider Activity
The most recent 5 insider filings for InnerScope Hearing Technologies, Inc. break down as 5 sales and 0 purchases. On net that is roughly 5K shares disposed (about $1K), a signal worth weighing alongside the fundamentals.
INND Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio including hearing aids, therapeutic treatments, supplements, and CBD oil.
- Integrated business model with direct-to-consumer sales, wholesale, and owned clinics.
- Proprietary B2B SaaS platform for patient management, offering a scalable service.
- Focus on affordable hearing solutions addresses a significant market demand.
Bear Case
- Significant unprofitability with negative profit margin (-267.1%) and gross margin (-81.5%).
- Very low market capitalization ($0.00B, or $613) indicating microcap status and high risk.
- Trades on the OTC Other tier, implying limited liquidity and disclosure.
- Small employee base (26 employees) for a company with diverse operations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
INND Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Feb 11, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 17, 2019
INND Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INND.
Price Targets
Wall Street price target analysis for INND.
INND MoonshotScore
What does this score mean?
The MoonshotScore rates INND's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Matthew Ross Moore
CEO
Matthew Ross Moore serves as the Chief Executive Officer of InnerScope Hearing Technologies, Inc., overseeing the company's strategic direction and day-to-day operations. His leadership is central to managing the company's 26 employees and guiding its diverse business segments, which span from the manufacturing and direct-to-consumer sales of hearing devices to the operation of audiological clinics and the provision of B2B software solutions. Moore's tenure has involved navigating the company's evolution from its founding as Innerscope Advertising Agency, Inc. in 2012 to its current focus on hearing technologies since its name change in August 2017.
Track Record: Under Matthew Ross Moore's leadership, InnerScope Hearing Technologies, Inc. has expanded its offerings to include a comprehensive suite of hearing solutions, encompassing both hardware and related services. He has overseen the establishment and operation of eleven audiological and retail hearing device clinics, alongside the development of a B2B SaaS platform for patient management. His strategic decisions have focused on diversifying revenue streams and addressing the market for affordable hearing technology.
INND OTC Market Information
InnerScope Hearing Technologies, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing requirements regarding financial health, market capitalization, and corporate governance, OTC Other companies face minimal disclosure obligations. This tier is typically for companies that do not meet the standards for OTCQX or OTCQB, often due to financial distress, bankruptcy, or a lack of public information. Consequently, stocks on this tier are considered highly speculative and carry elevated risks for investors due to limited transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The "Unknown" disclosure status means investors have minimal access to current financial reports and operational updates, hindering informed decision-making.
- Extreme Volatility: The microcap status and OTC Other tier listing make the stock highly susceptible to large price swings based on minimal trading volume or news.
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume and wide bid-ask spreads, potentially leading to significant losses if an exit is needed quickly.
- No Exchange Oversight: Lack of regulatory oversight compared to major exchanges means fewer investor protections and higher potential for manipulative trading practices.
- Difficulty in Raising Capital: The company may struggle to attract institutional investment or secure financing due to its speculative nature and lack of transparency.
- Verify the company's financial statements and audit reports, if available, from independent sources.
- Research the management team's background, experience, and any past regulatory issues.
- Assess the company's business plan and competitive landscape to understand its viability.
- Examine any recent news releases or corporate actions for red flags or significant developments.
- Understand the current share structure, including outstanding shares and potential dilution risks.
- Evaluate the company's ability to generate revenue and achieve profitability given its negative margins.
- Consider the overall market sentiment and any specific risks associated with the OTC Other tier.
- Operates eleven audiological and retail hearing device clinics, indicating tangible physical operations.
- Provides a B2B SaaS platform for patient management, suggesting a commitment to technology and service.
- Offers a diversified product line including hardware, therapeutic treatments, and specialized supplements.
- Has a stated corporate headquarters in Roseville, California.
InnerScope Hearing Technologies, Inc. Healthcare Stock: Key Questions Answered
What revenue streams does InnerScope Hearing Technologies, Inc. have in healthcare?
InnerScope Hearing Technologies, Inc. generates revenue through a diverse set of channels within the healthcare sector. Primarily, it earns income from the manufacturing and direct-to-consumer sales of its hearing aids and personal sound amplification devices. This direct sales model allows for broader market reach. Additionally, the company supplies these devices to the retail hearing aid community, generating wholesale revenue. A significant portion of its service-based revenue comes from the operation of its eleven audiological and retail hearing device clinics, where it provides professional services and product sales. Furthermore, InnerScope diversifies its income through the sale of physician-developed dietary supplements for hearing health and a unique CBD oil formulated for tinnitus management. Lastly, it offers a business-to-business (B2B) software-as-a-service (SaaS) platform for patient management, generating recurring subscription fees from healthcare providers.
How does InnerScope Hearing Technologies, Inc. address the market for affordable hearing solutions?
InnerScope Hearing Technologies, Inc. addresses the market for affordable hearing solutions primarily through its direct-to-consumer (D2C) distribution model. By manufacturing and selling hearing aids and personal sound amplification devices directly to end-users, the company aims to reduce the costs associated with traditional retail channels and intermediaries. This approach allows InnerScope to offer its products at more competitive price points, making hearing technology more accessible to a wider demographic, particularly those who might be deterred by the higher costs of conventional hearing aids. The company's focus on both hearable and wearable forms of these devices further expands its appeal to consumers seeking convenient and cost-effective options for managing their hearing health. This strategy aligns with the growing demand for accessible healthcare solutions driven by an aging population.
What are the key operational challenges for InnerScope Hearing Technologies, Inc. given its financial performance?
InnerScope Hearing Technologies, Inc. faces significant operational challenges, prominently highlighted by its financial performance metrics. The company's profit margin of -267.1% indicates substantial unprofitability, meaning its expenses far exceed its revenues. This is further exacerbated by a negative gross margin of -81.5%, suggesting that the cost of producing or acquiring its goods and services is significantly higher than the revenue generated from their sale. These figures imply that InnerScope is struggling to cover its direct production costs, let alone its operating expenses, such as marketing, administration, and research and development. Addressing these margins requires either a substantial increase in sales volume, a significant reduction in the cost of goods sold, or a strategic adjustment in pricing. Sustaining operations and funding growth initiatives will be difficult without improving these fundamental profitability metrics.
What is InnerScope Hearing Technologies, Inc.'s strategy for growth in the competitive hearing aid market?
InnerScope Hearing Technologies, Inc.'s growth strategy in the competitive hearing aid market is multi-faceted, focusing on diversification and accessibility. The company aims to expand its direct-to-consumer (D2C) sales channels for its affordable hearing aids and personal sound amplification devices, leveraging digital platforms to reach a broader audience. Simultaneously, it seeks to grow its network of eleven audiological and retail hearing device clinics, which provide direct patient care and professional services, fostering customer loyalty. A key differentiator is its expansion into related healthcare products, including physician-developed dietary supplements for hearing health and a unique CBD oil for tinnitus management, tapping into the wellness market. Furthermore, its B2B SaaS platform for patient management offers a scalable revenue stream by serving other healthcare providers, integrating technology into its growth plan.
What are the key factors to evaluate for INND?
Evaluate INND on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does INND data refresh on this page?
INND prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INND's recent stock price performance?
InnerScope Hearing Technologies, Inc. (INND) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio including hearing aids, therapeutic treatments, supplements, and CBD oil. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INND overvalued or undervalued right now?
Valuing InnerScope Hearing Technologies, Inc. (INND) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is solely based on provided source data.
- Financial metrics are as of the last available data point.
- Market capitalization is extremely low ($613) as per AI Insight, impacting liquidity and risk assessment.
- No analyst coverage or price targets were provided in the source data.